Here are the 424B prospectus supplements from Flora Growth Corp. (FLGC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow FLGC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLGC filings page.
Flora Growth Corp. plans a primary offering of common shares under its shelf registration to raise cash. The company expects to use the proceeds to advance an AI-focused asset management strategy centered on cryptocurrency, particularly 0G tokens, and for working capital and general corporate purposes.
Flora, which will rebrand as ZeroStack Corp., now combines a digital asset treasury business with global pharmaceutical distribution through its German subsidiary Phatebo. It has exited its legacy hemp and cannabis operations and is positioning itself around decentralized AI infrastructure and international specialty drug distribution.
Flora Growth Corp. files a supplement to its prospectus supplement to suspend its at-the-market equity offering program. The company had authority to sell up to $3,450,000 of common shares through an ATM sales agreement with Revere Securities LLC. This Supplement suspends the ATM and terminates continuous offering, effective on January 27, 2026, and states no shares have been sold under the Sales Agreement.